BofA raised the firm’s price target on Ascendis Pharma (ASND) to $230 from $227 and keeps a Buy rating on the shares after partner Teijin Limited received manufacturing and marketing approval for Yorvipath in Japan for the treatment of hypoparathyroidism. The firm, which adds the Japan opportunity to its model, maintains a “bullish outlook” on the global Yorvipath opportunity, estimating peak sales of $3.2B.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma: Buy Rating Affirmed on Yorvipath Approval and TransCon CNP Prospects
- Ascendis Pharma price target raised to $260 from $254 at JPMorgan
- Ascendis Pharma Grants Employee Warrants to Foster Growth
- Ascendis Pharma A/S Q2 Earnings Call Highlights Growth
- UnitedHealth Stock (UNH) Tumbles 50% YTD; Here’s How to Buy the Dip Without the Risk